---
title: "Enfuvirtide"
canonical_url: https://peptidelibrary.app/library/enfuvirtide
description: "FDA-approved HIV-1 fusion inhibitor (Fuzeon) for treatment-experienced patients."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Enfuvirtide

Enfuvirtide (also called Fuzeon or T-20) is an FDA-approved HIV fusion inhibitor. Enfuvirtide is a thirty-six-amino-acid peptide derived from the HR2 region of the HIV-1 envelope glycoprotein gp41. During viral entry gp41 must fold so that its HR1 and HR2 regions pack into a six-helix bundle, and it is the energy of that collapse that pulls the viral and cell membranes together.

FDA-approved HIV-1 fusion inhibitor (Fuzeon) for treatment-experienced patients.

Also known as: Fuzeon, T-20, DP-178.

## Classification

- Type: FDA-approved HIV fusion inhibitor
- Mechanism class: gp41 fusion inhibitor
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Enfuvirtide is a thirty-six-amino-acid peptide derived from the HR2 region of the HIV-1 envelope glycoprotein gp41. During viral entry gp41 must fold so that its HR1 and HR2 regions pack into a six-helix bundle, and it is the energy of that collapse that pulls the viral and cell membranes together. Enfuvirtide binds the exposed HR1 groove in the transient pre-hairpin intermediate and occupies the site HR2 would use, preventing the bundle from forming and arresting fusion before the viral core enters the cell. Because it acts outside the cell on a structural rearrangement rather than on an enzyme, it retains activity against virus resistant to reverse transcriptase and protease inhibitors.

Targets: HIV-1 gp41.

Origin: Synthetic peptide corresponding to gp41 HR2.

## Properties

- Molecular formula: C204H301N51O64
- Molecular weight: 4,491.4 g/mol
- CAS number: 159519-65-0
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 1
- Controlled human trials: 1
- Preclinical sources: 0
- Latest source: 2019

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. FUZEON (enfuvirtide) for injection — FDA prescribing information, revised 8/2019 (Drugs@FDA). 2019. Regulatory label (FDA), human. Population: Treatment-experienced adults with HIV-1 replication despite ongoing antiretroviral therapy. Treatment of HIV-1 infection [Source](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021481s033lbl.pdf)
2. FUZEON (enfuvirtide) for injection — FDA prescribing information, revised 8/2019 (Drugs@FDA). 2019. Regulatory label (FDA), human. Population: Treatment-experienced children with HIV-1 weighing at least 11 kg. Treatment of HIV-1 infection [Source](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021481s033lbl.pdf)
3. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003. 2003. Controlled human trial. Population: Adults with multidrug-resistant HIV-1 after at least six months of three drug classes (501 randomised). Mean viral load fell by 1.696 log10 copies/mL with enfuvirtide versus 0.764 with the background regimen alone; injection-site reactions in 98% of patients and more pneumonia with enfuvirtide [Source](https://pubmed.ncbi.nlm.nih.gov/12637625/)

## Safety

Side effects: Injection-site reactions (very common); Pneumonia signal; Hypersensitivity.

Risks: Must be used in combination ART; Twice-daily injections.

Human safety basis: FDA prescribing information

## Regulatory status

Enfuvirtide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- WADA status: Permitted
- Availability: Prescription-Only

## Frequently asked questions

### What is Enfuvirtide?

FDA-approved HIV-1 fusion inhibitor (Fuzeon) for treatment-experienced patients.

### How does Enfuvirtide work?

Enfuvirtide is a thirty-six-amino-acid peptide derived from the HR2 region of the HIV-1 envelope glycoprotein gp41. During viral entry gp41 must fold so that its HR1 and HR2 regions pack into a six-helix bundle, and it is the energy of that collapse that pulls the viral and cell membranes together.

### Is Enfuvirtide FDA approved?

Yes. Enfuvirtide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Enfuvirtide?

Reported half-life for Enfuvirtide is ~3.8 hours (sc). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Enfuvirtide banned in sport?

Enfuvirtide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Enfuvirtide?

Compounds most often compared with Enfuvirtide include Angiotensin II, Cetrorelix, Corticorelin and Cosyntropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [FDA label — Fuzeon](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021481s033lbl.pdf)
- [Enfuvirtide, 2012](https://pubmed.ncbi.nlm.nih.gov/31644169/)
- [Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor — Biochim Biophys Acta, 2011](https://pubmed.ncbi.nlm.nih.gov/21762676/)
- [Fuzeon-induced collagenophagic granuloma: a peculiar granulomatous injection site reaction to Fuzeon--a case report and review of literature — Int J Surg Pathol, 2010](https://pubmed.ncbi.nlm.nih.gov/19223380/)
- [\[Spanish recommendations for proper use of enfuvirtide\] — Enferm Infecc Microbiol Clin, 2007](https://pubmed.ncbi.nlm.nih.gov/17288910/)
- [Enfuvirtide, 2006](https://pubmed.ncbi.nlm.nih.gov/30000878/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
